Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers

British Journal of Cancer

Volumn 82, Issue 10, 2000, Pages 1724-1731

  Szepeshazi, K ^a,b   Schally, A V ^a,b   Groot, K ^a   Armatis, P ^a   Halmos, G ^a,b   Hebert, F ^a   Szende, B ^c   Varga, J L ^a,b   Zarandi, M ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

AgNOR; Apoptosis; Colon cancer; GH RH antagonists; IGF I; IGF I receptor; IGF II

Indexed keywords

GROWTH HORMONE RELEASING FACTOR; HORMONE ANTAGONIST; JV 1 36; MESSENGER RNA; MZ 4 71; MZ 5 156; SOMATOMEDIN B; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN HT29; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; HISTOLOGY; HORMONE BLOOD LEVEL; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CELL DIVISION; COLONIC NEOPLASMS; GROWTH HORMONE-RELEASING HORMONE; HT29 CELLS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; MICE; MICE, NUDE; NEOPLASM PROTEINS; NUCLEOLUS ORGANIZER REGION; RNA, MESSENGER; SERMORELIN; TRANSPLANTATION, HETEROLOGOUS;

EID: 0034110139     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Baserga R (1995) The insulin-like growth factor I receptor: a key to tumour growth. Cancer Res 55: 249-252
2. Bernhardt G, Reile H, Birnbock H, Spruss T and Shonenberger H (1992) Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity. J Cancer Res Clin Oncol 118: 35-43
3. Blakesley VA, Stannard BS, Kalebic T, Helman LJ and LeRoith D (1997) Role of the IGF-I receptor in mutagenesis and tumour promotion. J Endocrinol 152: 339-344
4. Csernus V, Schally AV and Groot K (1999) Antagonistic analogs of growth hormone-releasing hormone (GHRH) inhibit cyclic AMP production of human cancer cell lines in vitro. Peptides 20: 843-850
5. D'Ambrosio C, Ferber A, Resnicoff M and Baserga R (1996) A soluble insulin-like growth factor I receptor that induces apoptosis of tumour cells in vivo and inhibits tumorigenesis. Cancer Res 56: 4013-4020
6. elAtiq F, Garrouste F, Remacle-Bonnet M, Sastre B and Pommier G (1994) Alterations in serum levels of insulin-like growth factors and insulin-like growth-factor-binding proteins in patients with colorectal cancer. Int J Cancer 57: 491-497
7. Garrouste FL, Remacle-Bonnet MM, Lehmann NM-A, Marvaldi JL and Pommier GJ (1997) Up-regulation of insulin/insulin-like growth factor-I hybrid receptors during differentiation of HT29-D4 human colonic carcinoma cells. Endocrinology 138: 2021-2032
8. Hardcastle JD (1997) Colorectal cancer. CA-A Cancer J Clin 47: 66-69
9. Jones JI and Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocrine Rev 16: 3-34
10. Kiaris H and Schally AV (1999) Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone. Proc Natl Acad Sci USA 96: 226-231
11. Kovacs M, Zarandi M, Halmos G, Groot K and Schally AV (1996) Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: Mechanisms of action. Endocrinol 137: 5364-5369
12. Kovacs M, Schally AV, Zarandi M and Groot K (1997) Inhibition of GH release in rats by new potent antagonists of growth hormone-releasing hormone (GH-RH). Peptides 18: 431-438
13. Labianca R, Pessi MA and Zamparelli G (1997) Treatment of colorectal cancer. Drugs 53: 593-607
14. Lahm H, Suardet L, Laurent PL, Ficher JR, Ceyhan A, Givel J-C and Odartchenko N (1992) Growth regulation and co-stimulation of human colorectal cancer cell lines by insulin-like growth factor I, II and transforming growth factor α. Br J Cancer 65: 341-346
15. Lahm H, Amstad P, Yilmaz A, Fischer JR, Givel JC, Odartchenko N and Sordat B (1996) Differential effect of interleukin-4 and transforming growth factor beta 1 on expression of proto-oncogenes and autocrine insulin-like growth factor II in colorectal carcinoma cells. Biochem Biophys Res Commun 220: 334-340
16. Lamharzi N, Schally AV, Koppan M and Groot K (1998) Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II. Proc Natl Acad Sci USA 95: 8864-8868
17. Lelievre V, Meunier AC, Caigneaux E, Falcon J and Muller JM (1998) Differential expression and function of PACAP and VIP receptors in four human colonic adenocarcinoma cell lines. Cell Signal 10: 13-26
18. Lobie PE, Breipohl W and Waters MJ (1990) Growth hormone receptor expression in the rat gastrointestinal tract. Endocrinology 126: 299-306
19. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH and Stampfer MJ (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91: 620-625
20. Macaulay VM (1992) Insulin-like growth factors and cancer. Br J Cancer 65: 311-320
21. Magnusson BA, Raju RVS, Moyana TN and Sharma RK (1995) Increased N-myristoyl-transferase activity observed in rat and human colonic tumours. J Natl Cancer Inst 87: 1630-1635
22. Mayo KE (1992) Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Molec Endocrin 6: 1734-1744
23. Michell NP, Langman MJS and Eggo MC (1997) Insulin-like growth factors and their binding proteins in human colonocytes: preferential degradation of insulin-like growth factor binding protein 2 in colonic cancers. Brit J Cancer 76: 60-66
24. Mohan S and Baylink DJ (1996) Editorial: Insulin-like growth factor (IGF)-binding proteins in serum - do they have additional roles besides modulating the endocrine IGF actions? J Clin Endocrinol Metab 81: 3817-3820
25. Munson PJ and Rodbard D (1980) Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107: 220-239
26. Orme SM, McNally RJQ, Cartwright RA and Belchetz PE (1998) Mortality and cancer incidence in acromegaly: A retrospective cohort study. J Clin Endocrinol Metab 83: 2730-2734
27. Pinski J, Schally AV, Groot K, Halmos G, Szepeshazi K, Zarandi M and Armatis P (1995) Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone. J Natl Cancer Inst 87: 1787-1794
28. Pollak MN and Schally AV (1998) Mechanism of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med 217: 143-152
29. Pollak MN, Perdue JF, Margolese RG, Baer K and Richard M (1987) Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett 38: 223-230
30. Pollak M, Polychronakos C and Guyda H (1989) Somatostatin analogue SMS 201-995 reduces serum IGF-1 levels in patients with neoplasms potentially IGF-I dependent. Anticancer Research 9: 889-891
31. 121I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer. Br J Cancer 78: 1-5
32. Reubi JC (1995) In vitro identification of vasoactive intestinal peptide receptors in human tumours: implications for tumour imaging. J Nucl Med 36: 1846-1853
33. Schally AV (1994) Hypothalamic hormones: from neuroendocrinology to cancer therapy. Anti-Cancer Drugs 5: 115-130
34. Schally AV, Kovacs M, Toth K and Comaru-Schally AM (1998) Antagonistic analogs of growth hormone-releasing hormone (GH-RH): endocrine and oncological studies. In: Bercu BB, Walker RF, eds. Growth hormone secretagogues in clinical practice. New York: Marcel Dekker: 145-162
35. Singh P and Rubin N (1993) Insulinlike growth factors and binding proteins in colon cancer. Gastroenterology 105: 1218-1237
36. Singleton JR, Randolph AE and Feldman EL (1996) Insulin-like growth factor I receptor prevents apoptosis and enhances neuroblastoma tumorigenesis. Cancer Res 56: 4522-4529
37. Szepeshazi K, Korkut E and Schally AV (1991) Decrease in the AgNOR number in Dunning R3327 prostate cancers after treatment with an agonist and antagonist of luteinizing hormone-releasing hormone. Am J Pathol 138: 1273-1277
38. Toretsky JA and Helman LJ (1996) Involvement of IGF-II in human cancer. J Endocrinol 149: 367-372
39. Tricoli JV, Rall LB, Karakousis CP, Herera L, Petrelli NJ, Bell GI and Shows TB (1986) Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas. Cancer Res 46: 6169-6173
40. Varga JL, Schally AV, Csernus VJ, Zarandi M, Halmos G, Groot K and Rekasi Z (1999) Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities. Proc Natl Acad Sci (USA) 96: 692-697
41. Westley BR and May FEB (1995) Insulin-like growth factors: the unrecognised oncogenes. Br J Cancer 72: 1065-1066
42. Williams NN, Gyorfi T, Iliopoulos D, Herlyn D, Greenstein D, Linnenbach AJ, Daly JM, Jensen P, Rodeck U and Herlyn M (1992) Growth-factor-independence and invasive properties of colorectal carcinoma cells. Int J Cancer 50: 274-280
43. Zarandi M, Horvath JE, Halmos G, Pinski J, Nagy A, Groot K, Rekasi Z, Schally AV (1994) Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci USA 91: 12298-12301
44. Zarandi M, Kovacs M, Horvath JE, Toth K, Halmos G, Groot K, Nagy A, Kele Z, Schally AV (1997) Synthesis and in vitro evaluation of new potent antagonists of growth hormone-releasing hormone (GH-RH). Peptides 18: 423-430